Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | FPR1 | P21462 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749372 | 1.00 | NOTUM (0.44) | NOTUMNPY5RMCHR1FPR1FPR2 | |
| SCHEMBL4291539 | 0.90 | MCHR1 (0.49) | NOTUMNPY5RMCHR1FPR1FPR2 | |
| SCHEMBL1749968 | 0.86 | GAA (0.43) | NOTUMMCHR1SETD2NSD2CHRM4 | |
| SCHEMBL1749590 | 0.86 | NOTUM (0.51) | NOTUMMCHR1CHRM4 | |
| SCHEMBL1749532 | 0.85 | MCHR1 (0.42) | NOTUMNPY5RMCHR1CHRM4MAP4K4 | |
| SCHEMBL31084534 | 0.84 | FPR1 (0.44) | NOTUMNPY5RMCHR1FPR1FPR2 | |
| SCHEMBL4263614 | 0.84 | FPR1 (0.44) | NOTUMNPY5RMCHR1FPR1FPR2 | |
| SCHEMBL4259168 | 0.84 | FPR1 (0.44) | NOTUMNPY5RMCHR1FPR1FPR2 | |
| SCHEMBL4259518 | 0.84 | PDE10A (0.43) | NOTUMNPY5RMCHR1FPR1FPR2 | |
| SCHEMBL27760852 | 0.84 | PDE10A (0.43) | NOTUMNPY5RMCHR1FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | NOTUM 2483/4885NPY5R 2277/4885MCHR1 1838/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | NOTUM 2170/4885NPY5R 1978/4885MCHR1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.